Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

Status:

Closed to Accrual

III

Phase

Adjuvant

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

PD-1, PD-L1

Investigational

Product

Nivolumab

Treatment Arms

o Ipilimumab and Placebo matching Nivolumab

o Nivolumab and Placebo matching Ipilimumab